Volume 29, Number 3—March 2023
Dispatch
SARS-CoV-2 Incubation Period during the Omicron BA.5–Dominant Period in Japan
Tsuyoshi Ogata
and Hideo Tanaka
and Hideo Tanaka
Table 2
Correlations between incubation period and different patient characteristics in study of SARS-CoV-2 incubation period during the Omicron BA.5-dominant period in Japan*
| Variables | No. patients | Incubation period, mean no. d (SD) | p value |
|---|---|---|---|
| Total no. patients |
122 |
2.6 (1.0) |
NA |
| Infectee variables | |||
| Sex | 0.07 | ||
| M | 55 | 2.8 (1.0) | NA |
| F | 67 | 2.5 (1.0) | NA |
| Age, y | 0.13 | ||
| <19 | 32 | 2.8 (1.2) | NA |
| >20 | 90 | 2.6 (0.9) | NA |
| No. vaccinations | 0.66 | ||
| 0–2 | 54 | 2.6 (1.0) | NA |
| 3 | 68 | 2.6 (1.0) | NA |
| Transmission—shared meals | 0.03 | ||
| Yes | 90 | 2.5 (0.9) | NA |
| No |
32 |
2.9 (1.1) |
NA |
| Infector variables | |||
| Sex | 0.68 | ||
| M | 68 | 2.7 (1.0) | NA |
| F | 54 | 2.5 (1.0) | NA |
| Age, y | 0.007 | ||
| <19 | 27 | 3.0 (1.2) | NA |
| >20 | 95 | 2.5 (0.9) | NA |
| No. vaccinations | 0.83 | ||
| 0–2 | 59 | 2.7 (1.0) | NA |
| 3 | 63 | 2.6 (0.9) | NA |
*We performed multivariable gamma regression analyses of patients during the SARS-CoV-2 Omicron BA.5–dominant period in Japan. NA, not applicable.
Page created: January 05, 2023
Page updated: February 20, 2023
Page reviewed: February 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.